|
|
|
Cancer Personalized Medicine:
Technology and Market Analysis Business Tutorial
13:30—17:00, 4 September 2008, Amsterdam, The Netherlands
Course Tutor: Enal Razvi, Ph.D.
This tutorial will be held immediately following the Stem Cells Europe Conference.
Introduction and Focus of this Business Tutorial
The focus of this tutorial is to present the technology and market landscape of the cancer personalized medicine space based on our recent tracking of this space. Select Biosciences has recently published its market report, Cancer Personalized Medicine 2008, in July 2008 based on this industry tracking. This industry analysis is an up-to-date and comprehensive picture of the landscape of personalized medicine as it impacts cancer. This industry analysis, albeit focused on the cancer personalized medicine space, provides the framework for the types of technologies, products, and markets that personalized medicine across the therapeutics landscape is expected to impact, and the quantitative impact that is predicted. New biomarker classes such as microRNAs and Epigenetics will be emphasized at this tutorial and details of their market landscape will be analyzed.
Each tutorial attendee will receive electronic copies of the materials presented at this tutorial, as well as key reference material on CD. Also, attendees will have the opportunity to purchase Select Biosciences latest industry report on Cancer Personalized Medicine—at a significant savings over the normal retail price for the report—as part of a special package. This is an option [tutorial + report] on the Registration page in the left-hand column of this page.
Specific Topics Covered in this Tutorial
- Overview and Introduction to the Cancer Personalized Medicine Marketplace
- All the Various Breast Cancer Companion Diagnostic Tests on the Market and in Development—Characteristics, Technology Platforms Utilized, Biomarkers Utilized, Features/Benefits, Addressable Patient Populations, Regulatory Status, Cost per Test
- Companion Diagnostics/Therapeutics for Other Cancer Classes—A Thorough Analysis Across the Market Landscape
- Key Personalized Medicine Products in the Breast Cancer, Colon Cancer, etc. market spaces—together with the characteristics/features of These Products—HER2, oncotype DX™, MammaPrint®, UGT1A1, K-RAS, EGFR, etc.
- Warfarin Personalized Medicine as a Paradigm for the Personalized Medicine Marketplace—Biology, Markers Utilized, Landscape of Currently FDA-approved Tests
- Worldwide Market Survey of Cancer Personalized Medicine—Qualitative and Quantitative Market Metrics:
- Market Breakout by Types of Markers Currently Used
- Market Breakout by Types of Markers Forecast for the Future
- Challenges and Drivers of Market Adoption
- Market Opportunity for Cancer Personalized Medicine in Different Segments of the Cancer Marketplace
- Technologies Utilized in Different Cancer Segments in Companion Diagnostics
- Market Trends in microRNAs and Epigenetics as Cancer Diagnostic Biomarkers
- Market Forecast in Terms of Industry Revenues—2008 through 2011
- Emerging Trends in Cancer Biomarkers: MicroRNAs and Epigenetics
- Predicted Impact of microRNA-based Diagnostics and microRNA-based Therapeutics On Various Segments of the Cancer Marketplace
- RNAi-based Therapeutics Landscape for Cancer: Industry Participants, Biomarker Addressed, Status of Clinical Pipeline, Relevant Partnerships
- Survey of the key market participants in the space
Who Should Attend
- Business development professionals seeking an up-to-date view of the personalized medicine landscape
- Researchers, research directors, scientists from large and small companies seeking an up-to-date view of the market and emerging opportunities therein
- Academics seeking to assess the market opportunities in their research areas
- Investment community, venture capital investors, seeking a market and technology overview in order to assess companies in the landscape for investment considerations
Areas of Select Biosciences Business Coverage
- Stem Cells for Regenerative Medicine
- Stem Cells in Drug Discovery & Development, Toxicity Screening
- MicroRNA Research Tools and Technologies
- MicroRNA Diagnostics and Therapeutics
- Epigenetics
- RNAi Tools and Technologies
- RNAi Therapeutics
- Personalized Medicine
- Key Drug Targets: GPCRs and Kinases
|